secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2026-05-14T11:53:38+00:00
Accession:  0001730463-26-000058
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus Q1 2026: AUCATZYL net revenue $26.2M; positive gross margin; reaffirms FY revenue $120-135M
--------------------------------------------------------------------------------

- Net product revenue $26.2M (vs $9.0M Q1 2025); gross profit $1.6M, first positive quarter for ALL business.
- Net loss $71.6M ($0.27 loss per share); cash equivalents $229.4M, down from $300.7M at Dec 2025.
- Reaffirms FY2026 AUCATZYL net product revenue guidance $120-135M; expects continued positive gross margin.
- Cost reduction: ~13% workforce cut; annualized savings ~$15M starting 2027; restructuring charges ~$8M.
- Clinical pipeline on track: pediatric ALL data end-2027; lupus nephritis data 2028; progressive MS initial data end-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/0001730463-26-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/autl-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001730463-26-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer